ProPhase Labs, Inc.

How big is ProPhase Labs, Inc.?

As of Jun 18, ProPhase Labs, Inc. has a market capitalization of 19.07 million and reported net sales of 10.68 million with a net profit of -23.68 million over the last four quarters. Shareholder's funds are 7.35 million, and total assets amount to 63.20 million.

As of Jun 18, ProPhase Labs, Inc. has a market capitalization of 19.07 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 10.68 million, while the sum of net profit for the same period is -23.68 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 7.35 million, and total assets amount to 63.20 million.

What does ProPhase Labs, Inc. do?

ProPhase Labs, Inc. manufactures and distributes homeopathic and healthcare products in the Pharmaceuticals & Biotechnology sector. As of March 2025, it reported net sales of $1 million and a net loss of $5 million, with a market cap of $19.07 million.

Overview:<BR>ProPhase Labs, Inc. manufactures, markets, and distributes a range of homeopathic and healthcare products within the Pharmaceuticals & Biotechnology industry, operating in the micro-cap market.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 1 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -5 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 19.07 Million (Micro Cap)<BR><BR>Key Metrics:<BR>Debt Equity: 0.48 <BR>Return on Equity: -149.07% <BR>Price to Book: 1.22 <BR><BR>Contact Details:<BR>Address: 711 STEWART AVENUE, GARDEN CITY, NEW YORK NY: 11530 <BR>Tel: 1 215 3450919 <BR>Website: http://www.prophaselabs.com/

Should I buy, sell or hold ProPhase Labs, Inc.?

Who are in the management team of ProPhase Labs, Inc.?

As of March 2022, the management team of ProPhase Labs, Inc. includes Mr. Ted Karkus as Chairman and CEO, along with independent directors Mr. Jason Barr, Dr. Louis Gleckel, and Mr. Warren Hirsch.

As of March 2022, the management team of ProPhase Labs, Inc. includes Mr. Ted Karkus, who serves as the Chairman of the Board and Chief Executive Officer. Additionally, the board features independent directors: Mr. Jason Barr, Dr. Louis Gleckel, and Mr. Warren Hirsch.

Is ProPhase Labs, Inc. overvalued or undervalued?

As of August 10, 2023, ProPhase Labs, Inc. is considered risky and overvalued due to its negative P/E ratio, poor returns on capital, and significant underperformance compared to peers and the S&P 500.

As of 10 August 2023, the valuation grade for ProPhase Labs, Inc. has moved from expensive to risky, indicating a significant deterioration in its financial standing. The company appears to be overvalued, particularly given its negative P/E ratio and troubling returns on capital, with a ROCE of -119.77% and an ROE of -149.07%. The Price to Book Value stands at 1.25, while the EV to Sales ratio is notably high at 2.53, suggesting that investors are paying a premium despite the company's losses.<BR><BR>In comparison to its peers, ProPhase Labs, Inc. has a less favorable valuation profile, with Chromadex Corp. showing a P/E of 39.82 and EV to EBITDA of 36.56, indicating a more robust market position. Similarly, LifeVantage Corp. is valued more attractively with a P/E of 14.81 and EV to EBITDA of 8.26. The company's stock has underperformed significantly against the S&P 500, with a year-to-date return of -44.83% compared to the index's 12.22%, and a staggering 1-year return of -82.95% versus 17.14% for the S&P 500.

Is ProPhase Labs, Inc. technically bullish or bearish?

As of September 10, 2025, ProPhase Labs, Inc. shows a mildly bullish technical trend driven by MACD and RSI indicators, despite underperforming the S&P 500 with a year-to-date return of -44.83%.

As of 10 September 2025, the technical trend for ProPhase Labs, Inc. has changed from sideways to mildly bullish. The weekly and monthly MACD indicators are both mildly bullish, while the monthly RSI is bullish. However, the daily moving averages indicate a mildly bearish stance. The Bollinger Bands show a mixed signal with a mildly bullish weekly and a mildly bearish monthly. The KST is mildly bearish weekly and bearish monthly, while the Dow Theory indicates a mildly bullish monthly trend. Overall, the technical stance is mildly bullish, driven primarily by the MACD and monthly RSI.<BR><BR>In terms of performance, the stock has underperformed significantly against the S&P 500 across multiple periods, with a year-to-date return of -44.83% compared to the S&P 500's 12.22%, and a one-year return of -82.95% versus 17.14% for the index.